All questions
Safety: Zepbound (tirzepatide) in chronic weight management 9 questions · 3 sources
Safety questions that apply to every indication of Zepbound are on Zepbound (tirzepatide), all indications: Safety .
Side effects Zepbound vs Wegovy: how do the side effects compare (SURMOUNT-5)? Note: SURMOUNT-5 results are from the clinical data page of the Zepbound HCP site; the Zepbound Prescribing Information does not describe this trial.
What are the most common side effects of Zepbound? “Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2)
a Includes diarrhea, frequent bowel movements.
b Includes constipation, feces hard.
c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness.
d Includes multiple related adverse event terms, such as injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash, injection site reaction.
e Includes asthenia, fatigue, lethargy, malaise.
f Includes blood pressure decreased, hypotension, orthostatic hypotension.
Adverse Reaction
Placebo
(N=958)
% ZEPBOUND
5 mg
(N=630)
% ZEPBOUND
10 mg
(N=948)
% ZEPBOUND
15 mg
(N=941)
%
Nausea 8 25 29 28
Diarrheaa 8 19 21 23
Vomiting 2 8 11 13
Constipationb 5 17 14 11
Abdominal Painc 5 9 9 10
Dyspepsia 4 9 9 10
Injection Site Reactionsd 2 6 8 8
Fatiguee 3 5 6 7
Hypersensitivity Reactions 3 5 5 5
Eructation 1 4 5 5
Hair Loss 1 5 4 5
Gastroesophageal Reflux Disease 2 4 4 5
Flatulence 2 3 3 4
Abdominal Distension 2 3 3 4
Dizziness 2 4 5 4
Hypotensionf 0 1 1 2” (opens the source at this quote in a new tab) Copy Flag
Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients). The clinical data page of the Zepbound HCP site presents the same pooled rates as SURMOUNT-1 and SURMOUNT-2.
How common is nausea on Zepbound? Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients).
Does Zepbound nausea go away? Note: The first passage is from the pooled Study 1 and Study 2 results of the Prescribing Information. The second is from SURMOUNT-MAINTAIN on the clinical data page of the Zepbound HCP site; the Prescribing Information does not describe that trial.
How can Zepbound nausea and stomach side effects be reduced? Note: The eating suggestions are from the dosing page of the Zepbound HCP site, which cites published reviews of medication-related nausea and GLP-1 receptor agonist use; they do not appear in the Prescribing Information.
How many people stop taking Zepbound because of side effects? What are the long-term side effects of Zepbound (SURMOUNT-MAINTAIN)? “Table showing the adverse events that emerged during treatment and occurred in ≥5% of participants in any treatment group in SURMOUNT-MAINTAIN. Deaths occurred in <1% of participants taking Zepbound MTD (10 mg or 15 mg) (n=441) from week 0 to week 60. From week 60 to week 112, deaths occurred in 0% of patients who received Zepbound MTD (10 mg or 15 mg) (n=139), who had their dose reduced to Zepbound 5 mg (n=142), or who were switched to placebo (n=91). From week 0 to week 60, participants taking Zepbound MTD (10 mg or 15 mg) (n=441) experienced: nausea: 35%, vomiting: 17%, diarrhea: 24%, constipation: 31%, eructation: 8%, dyspepsia: 7%, gastroesophageal reflux disease: 7%, abdominal pain: 6%, abdominal distension: 5%, upper respiratory tract infection: 7%, COVID-19: 7%, influenza: 5%, sinusitis: 3%, urinary tract infection: 3%, injection site reaction: 9%, fatigue: 10%, headache: 9%, dizziness: 7%, decreased appetite: 5%, and alopecia: 9%. Participants taking Zepbound MTD (10 mg or 15 mg) (n=139) experienced from week 60 to week 112: nausea: 6%, vomiting: 6%, diarrhea: 7%, constipation: 1%, eructation: 3%, dyspepsia: 2%, gastroesophageal reflux disease: 1%, abdominal pain: 1%, abdominal distension: 3%, upper respiratory tract infection: 1%, COVID-19: 1%, influenza: 4%, sinusitis: 5%, urinary tract infection: 5%, injection site reaction: 6%, fatigue: 1%, headache: 2%, dizziness: 1%, decreased appetite: 0%, and alopecia: 1%. Participants who had their dose reduced to Zepbound 5 mg (n=142) experienced from week 60 to week 112: nausea: 4%, vomiting: 1%, diarrhea: 5%, constipation: 4%, eructation: 1%, dyspepsia: 1%, gastroesophageal reflux disease: 1%, abdominal pain: 1%, abdominal distension: 1%, upper respiratory tract infection: 4%, COVID-19: 3%, influenza: 1%, sinusitis: 5%, urinary tract infection: 1%, injection site reaction: 2%, fatigue: 0%, headache: 4%, dizziness: 1%, decreased appetite: 0%, and alopecia: 0%. Participants who were switched to placebo (n=91) experienced from week 60 to week 112: nausea: 2%, vomiting: 0%, diarrhea: 1%, constipation: 4%, eructation: 0%, dyspepsia: 0%, gastroesophageal reflux disease: 1%, abdominal pain: 0%, abdominal distension: 1%, upper respiratory tract infection: 2%, COVID-19: 0%, influenza: 4%, sinusitis: 0%, urinary tract infection: 0%, injection site reaction: 0%, fatigue: 0%, headache: 3%, dizziness: 0%, decreased appetite: 0%, and alopecia: 0%.” (opens the source at this quote in a new tab) Copy Flag
On the page, select: Show description
Note: SURMOUNT-MAINTAIN is not described in the Zepbound Prescribing Information.
Does Zepbound cause hair loss? Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients).
Does Zepbound increase heart rate?